Şuayib Yalçın

Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial

Kohei Shitara, Toshihiko Doi, Mikhail Dvorkin et al. · The Lancet Oncology · 2018 · 520 citations

Medicine, Oncology, Pharmacology +12

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

Medicine, Oncology, Pharmacology +12

Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment‐use trial of sunitinib

Peter Reichardt, Yoon‐Koo Kang, Piotr Rutkowski et al. · Cancer · 2015 · 106 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Bone Metastasis from Gastric Cancer: The Incidence, Clinicopathological Features, and Influence on Survival

Fatma Paksoy Türköz, Mustafa Solak, Arife Ulaş et al. · Journal of the Korean Gastric Cancer Association · 2014 · 81 citations · Full text

Medicine, Oncology, Surgery +17

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Arlene O. Siefker‐Radtke, Nobuaki Matsubara, S.H. Park et al. · Annals of Oncology · 2023 · 80 citations · Full text

Medicine, Oncology, Pharmacotherapy +16